Uniqure NV - ESG Rating & Company Profile powered by AI
Other corporations in the rating industry group for Uniqure NV are displayed. The page displays a zero-cost Sustainability assessment for Uniqure NV. The dashboard contains a questions and answers section for Uniqure NV.
Uniqure NV in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.6; made up of an environmental score of 6.0, social score of 3.2 and governance score of 1.6.
3.6
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1132 | Taro Pharmaceutical Industries Ltd | 3.7 | Medium |
| 1132 | Traphaco JSC | 3.7 | Medium |
| 1144 | Uniqure NV | 3.6 | Medium |
| 1144 | CellSeed Inc | 3.6 | Medium |
| 1144 | Cellectar Biosciences Inc | 3.6 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Uniqure NV have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Uniqure NV disclose current and historical energy intensity?
Sign up for free to unlockDoes Uniqure NV report the average age of the workforce?
Sign up for free to unlockDoes Uniqure NV reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Uniqure NV disclose its ethnicity pay gap?
Sign up for free to unlockDoes Uniqure NV disclose cybersecurity risks?
Sign up for free to unlockDoes Uniqure NV offer flexible work?
Sign up for free to unlockDoes Uniqure NV have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Uniqure NV disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Uniqure NV conduct supply chain audits?
Sign up for free to unlockDoes Uniqure NV disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Uniqure NV conduct 360 degree staff reviews?
Sign up for free to unlockDoes Uniqure NV disclose the individual responsible for D&I?
Sign up for free to unlockDoes Uniqure NV disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Uniqure NV disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Uniqure NV disclose water use targets?
Sign up for free to unlockDoes Uniqure NV have careers partnerships with academic institutions?
Sign up for free to unlockDid Uniqure NV have a product recall in the last two years?
Sign up for free to unlockDoes Uniqure NV disclose incidents of discrimination?
Sign up for free to unlockDoes Uniqure NV allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Uniqure NV issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Uniqure NV disclose parental leave metrics?
Sign up for free to unlockDoes Uniqure NV disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Uniqure NV disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Uniqure NV disclose the pay ratio of women to men?
Sign up for free to unlockDoes Uniqure NV support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Uniqure NV disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Uniqure NV reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Uniqure NV involved in embryonic stem cell research?
Sign up for free to unlockDoes Uniqure NV disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Uniqure NV disclose its waste policy?
Sign up for free to unlockDoes Uniqure NV report according to TCFD requirements?
Sign up for free to unlockDoes Uniqure NV disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Uniqure NV disclose energy use targets?
Sign up for free to unlockDoes Uniqure NV disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Uniqure NV have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Uniqure NV
These potential risks are based on the size, segment and geographies of the company.
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.